English Polski
Vol 16, No 1 (2021)
Original paper
Published online: 2021-02-27

open access

Page views 1767
Article views/downloads 660
Get Citation

Connect on Social Media

Connect on Social Media

Transcatheter closure of patent foramen ovale in patients with cryptogenic stroke- impact on arrhythmia in 3 months follow-up

Andrzej Wittczak12, Marek Maciejewski3, Tomasz Moszura4, Paweł Dryżek4, Maciej Banach56, Agata Bielecka-Dąbrowa56
Folia Cardiologica 2021;16(1):8-15.

Abstract

Background: Patent foramen ovale (PFO) is a common abnormality, occurring in about 25% of the population. Percutaneous PFO closure is recommended for selected patients in the prevention of recurrent thromboembolic events. Although transcatheter closure of PFO is recognized as a safe procedure, potential complications, such as atrial fibrillation, may occur. The purpose of this study was to assess the prevalence of arrhythmia in patients before and after PFO closure. Methods: We retrospectively reviewed the medical records of 45 patients (median age, 45 [IQR, 35–61] years; 80% female) who underwent percutaneous PFO closure. 24‑hour Holter electrocardiograms were done both before and 3 months after the procedure in 21 patients (median age, 49 [38–65] years; 81% female), however data of predominant underlying rhythm was available for all 45 patients. Results: There were no statistically significant differences in maximal and minimal heart rate, number of supraventricular and ventricular extrasystolic beats, pauses, episodes of supraventricular and ventricular tachycardia in patients before and after the PFO closure procedure. Median average heart rate was significantly higher before the procedure (70 [67–78] bpm vs 69 [62–77] bpm; p = 0,03). Among the 45 patients, one had a history of paroxysmal atrial fibrillation (AF) before the procedure. During the follow‑up, no AF was found. Conclusions: 1) Transcatheter closure of PFO did not affect arrhythmias observed in 24‑hour Holter ECG monitoring of our patients. 2) The procedure has a low risk of complications if performed in selected patients by an adequately trained operator in an experienced center.

Article available in PDF format

View PDF Download PDF file

References

  1. Hara H, Virmani R, Ladich E, et al. Patent foramen ovale: current pathology, pathophysiology, and clinical status. J Am Coll Cardiol. 2005; 46(9): 1768–1776.
  2. Araszkiewicz A, Bartuś S, Demkow M, et al. Interventional closure of patent foramen ovale in prevention of thromboembolic events. Consensus document of the Association of Cardiovascular Interventions and the Section of Grown‑up Congenital Heart Disease of the Polish Cardiac Society. Kardiol Pol. 2019; 77(11): 1094–1105.
  3. Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology. 2000; 55(8): 1172–1179.
  4. Choong CK, Calvert PA, Falter F, et al. Life-threatening impending paradoxical embolus caught "red-handed": successful management by multidisciplinary team approach. J Thorac Cardiovasc Surg. 2008; 136(2): 527–528.e8.
  5. Grysiewicz RA, Thomas K, Pandey DK. Epidemiology of ischemic and hemorrhagic stroke: incidence, prevalence, mortality, and risk factors. Neurol Clin. 2008; 26(4): 871–95, vii.
  6. Hart RG, Diener HC, Coutts S, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014; 13(4): 429–438.
  7. Gąsiorek PE, Banach M, Maciejewski M, et al. Established and potential echocardiographic markers of embolism and their therapeutic implications in patients with ischemic stroke. Cardiol J. 2019; 26(5): 438–450.
  8. Ntaios G. Embolic stroke of undetermined source: JACC review topic of the week. J Am Coll Cardiol. 2020; 75(3): 333–340.
  9. Pristipino C, Sievert H, D'Ascenzo F, et al. Evidence Synthesis Team, Eapci Scientific Documents and Initiatives Committee, International Experts. European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. Eur Heart J. 2019; 40(38): 3182–3195.
  10. Chubb H, Whitaker J, Williams SE, et al. Pathophysiology and management of arrhythmias associated with atrial septal defect and patent foramen ovale. Arrhythm Electrophysiol Rev. 2014; 3(3): 168–172.
  11. Johnson JN, Marquardt ML, Ackerman MJ, et al. Electrocardiographic changes and arrhythmias following percutaneous atrial septal defect and patent foramen ovale device closure. Catheter Cardiovasc Interv. 2011; 78(2): 254–261.
  12. Anderson RH, Ho S, Becker A. Anatomy of the human atrioventricular junctions revisited. The Anatomical Record. 2000; 260(1): 81–91, doi: 10.1002/1097-0185(20000901)260:1<81::aid-ar90>3.0.co;2-3.
  13. Lemery R, Guiraudon G, Veinot J. Anatomic description of Bachmann’s bundle and its relation to the atrial septum. Am J Cardiol. 2003; 91(12): 1482–1485.
  14. Contractor T, Mandapati R. Arrhythmias in patients with atrial defects. Card Electrophysiol Clin. 2017; 9(2): 235–244.
  15. Turc G, Calvet D, Guérin P, et al. CLOSE Investigators. Closure, anticoagulation, or antiplatelet therapy for cryptogenic stroke with patent foramen ovale: systematic review of randomized trials, sequential meta-analysis, and new insights from the CLOSE study. J Am Heart Assoc. 2018; 7(12).
  16. Noble S, Bonvini RF, Rigamonti F, et al. Percutaneous PFO closure for cryptogenic stroke in the setting of a systematic cardiac and neurological screening and a standardised follow-up protocol. Open Heart. 2017; 4(1): e000475.
  17. Gevorgyan Fleming R, Kumar P, West B, et al. Comparison of residual shunt rate and complications across 6 different closure devices for patent foramen ovale. Catheter Cardiovasc Interv. 2020; 95(3): 365–372.
  18. Neuser J, Akin M, Bavendiek U, et al. Mid-term results of interventional closure of patent foramen ovale with the Occlutech Figulla Flex II Occluder. BMC Cardiovasc Disord. 2016; 16(1): 217.
  19. Hildick-Smith D, Williams T, MacCarthy P, et al. Occlutech percutaneous patent foramen ovale closure: safety and efficacy registry (OPPOSE). Int J Cardiol. 2017; 245: 99–104.
  20. Trabattoni D, Gaspardone A, Sgueglia GA, et al. AMPLATZER versus Figulla occluder for transcatheter patent foramen ovale closure. EuroIntervention. 2017; 12(17): 2092–2099.
  21. Saver JL, Carroll JD, Thaler DE, et al. RESPECT Investigators. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017; 377(11): 1022–1032.
  22. Mas JL, Derumeaux G, Guillon B, et al. CLOSE Investigators. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017; 377(11): 1011–1021.
  23. Søndergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke . N Engl J Med. 2017; 377(11): 1033–1042.
  24. Lee PH, Song JK, Kim JS, et al. Cryptogenic stroke and high-risk patent foramen ovale: the DEFENSE-PFO trial. J Am Coll Cardiol. 2018; 71(20): 2335–2342.
  25. Ateş AH, Sunman H, Aytemir K, et al. Prevention of recurrent cryptogenic stroke with percutaneous closure of patent foramen ovale; one year follow-up study with magnetic resonance imaging and Holter monitoring. Turk Kardiyol Dern Ars. 2015; 43(1): 38–46.